The clinical landscape of lymphomas has changed dramatically over the last 2 decades, including significant progress made in the understanding and utilization of imaging modalities and the available treatment options for both indolent and aggressive lymphomas. Since the introduction of hybrid PET/CT scanners in 2001, the indications of 18F-fluorodeoxyglucose (FDG) PET/CT in the management of lymphomas have grown rapidly. In today's clinical practice, FDG PET/CT is used in successful management of the vast majority patients with lymphomas.
Keywords: Deauville; FDG PET/CT; Fluorodeoxyglucose; Hodgkin; Lymphoma; Non-Hodgkin; Response assessment.
Copyright © 2023 Elsevier Inc. All rights reserved.